Current methods of testing for human papillomavirus

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 15, Issue 5, 2001, Pages 677-700

  Davies, Philip ^a   Kornegay, Janet ^b   Iftner, Thomas ^c  

^a Advanced Diagnostic Centre   (United Kingdom)

^b ROCHE MOLECULAR SYSTEMS   (United States)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Cervix neoplasms diagnosis; DNA; Papovaviridae infection diagnosis; Tumour virus infections diagnosis; Viral analysis

Indexed keywords

VIRUS DNA;

CANCER SCREENING; GENETIC ANALYSIS; HUMAN; HYBRIDIZATION; LABORATORY DIAGNOSIS; METHODOLOGY; MOLECULAR BIOLOGY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITY CONTROL; RELIABILITY; RESEARCH; REVIEW; TECHNOLOGY; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIROLOGY; VIRUS INFECTION; WART VIRUS;

EID: 0034750305     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1053/beog.2001.0214     Document Type: Article

References (46)

1. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia
2. International Biological Study on Cervical Cancer (IBSCC) study group. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective
3. Papillomavirus infections - A major cause of human cancers
4. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
5. Hybrid capture method for detection of human papillomavirus DNA in clinical specimens
6. Improved amplification of genital human papillomaviruses
7. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR
8. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses
9. Comparison of two tests for detecting carcinogenic HPV in women with Papanicolaou smear reports of ASCUS and LSIL
10. Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies
11. HPV testing in primary screening of older women
12. HPV DNA testing in cervical cancer screening: Results from women in a high risk province of Costa Rica
13. Identifying women with cervical neoplasia: Using human papillomavirus DNA testing for equivocal Papanicolaou results
14. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: Baseline results from a randomized trial
15. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: Baseline data from a randomised trial. The atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesions triage study (ALTS) group
16. Human papillomavirus testing in women with mild cytologic atypia
17. Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: A preliminary study on 1518 women
18. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer
19. Comparison of human papillomavirus detection and typing by cycle sequencing, line blotting, and hybrid capture
20. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: A prospective study
21. Causes of cervical cancer in the Philippines: A case-control study
22. Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses
23. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings
24. Genotyping of 27 human papillomavirus types by using LI consensus PCR products by a single-hybridization, reverse line blot detection method
25. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus
26. Determinants of genital cervical human papillomavirus detection in a US population
27. Non-isotopic detection of HPV DNA in clinical specimens using a consensus PCR and a generic probe mix in an ELISA format
28. Comparison of the hybrid capture tube test and PCR for detection of human papillomavirus DNA in cervical specimens
29. Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by hybrid capture II and polymerase chain reaction
30. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica
31. The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes
32. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy
33. Distribution of 14 high risk HPV types in cervical intraepithelial neoplasia detected by a non-radioactive general primer PCR mediated enzyme immunoassay
34. Short fragment polymerase chain reaction reverse hybridization line probe assay to detect and genotype a broad spectrum of human papillomavirus types. Clinical evaluation and follow-up
35. Where's the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses
36. PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes
37. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: The age-related patterns for high-risk and low-risk types
38. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears
39. PCR detection of human papillomavirus: Comparison between MY09/MY11 and GP5+/GP6+ primer systems
40. Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia
41. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type
42. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: A nested case-control study
43. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: A nested case-control study
44. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer
45. Precancer of the human cervix
46. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions